BioSpace News Archive

Integer Holdings Corporation announced that it plans to release financial and operational results for second quarter 2023, at 7 a.m. Central Time / 8 a.m. Eastern Time on Thursday, July 27, 2023.

Astellas Pharma Inc. and Mitsui Fudosan Co., Ltd. announced that Astellas will establish a “TME imaging and interactive research for innovation " open innovation hub in October, 2023 in “MITSUI LINK-Lab KASHIWA-NO-HA 1" operated by Mitsui Fudosan.

Curasight A/S announces positive results from the investigator-initiated phase II study using uPAR-PET in primary brain cancer.

GT Medical Technologies, Inc. has announced the promotion of Shane Brown to the position of President. Matthew Likens, currently President and CEO will continue in his role as Chief Executive Officer.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced positive top-line results from the Phase 2 clinical trial of intravitreal ADX-2191 (methotrexate injection, USP), an investigational drug candidate, in patients with retinitis pigmentosa.

Can-Fite BioPharma Ltd today announced that it received feedback and advice from the U.S. Food and Drug Administration (FDA) with respect to non-clinical and clinical development and registration plans for Piclidenoson for the treatment of patients with moderate to severe plaque psoriasis.

Advance ZincTek , Australia’s leading manufacturer of natural Sunscreen Actives, announces the launch of EcoZinc , the world’s first solar-powered, non-nano zinc oxide powder for SPF-rated cosmetics and sunscreens.

NeoGenomics, Inc. today announced the appointment of Elizabeth Floegel, Neil Gunn, and Tony Zook to its Board of Directors.

Antibe Therapeutics Inc. has filed its financial and operating results for the fiscal year ended March 31, 2023.

Emergex Vaccines Holding Limited, a clinical-stage biotechnology company addressing major global infectious diseases through the development of fully synthetic T cell-priming immune set-point candidates, announced the appointment of Sir Michael Rake as Chairman of the Board.